AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...
An attack campaign undertaken by a Vietnam-aligned hacking group known as OceanLotus (aka APT-Q-31) that delivers the Havoc post-exploitation framework in attacks targeting enterprises and government ...
Putting an exception like that aside, anyhow, this is a singer/songwriter record in the classic sense. “Returning to Myself” in this case involves sort of returning to the 1970s, a little bit, when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback